Chien‐Ying Huang

发表

The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium–glucose cotransporter 2 inhibitor

T. Chao, Shao‐Wei Chen, Yi-Wei Kao, 2021, Cardiovascular Diabetology.

The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors

T. Chao, Shao‐Wei Chen, Yi-Wei Kao, 2021, Cardiovascular Diabetology.

The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors

Shao‐Wei Chen, Yi-Wei Kao, P. Chu, 2020, Cardiovascular Diabetology.

Sodium glucose cotransporter‐2 inhibitor was associated with an improvement in left ventricular systolic function in patients with type 2 diabetes mellitus with impaired left ventricular systolic function

Yi-Wei Kao, P. Chu, Y. Chan, 2020, ESC heart failure.

Impact of the initial decline in estimated glomerular filtration rate on the risk of new‐onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium‐glucose co‐transporter‐2 inhibitors

T. Chao, Shao‐Wei Chen, Yi-Wei Kao, 2021, Diabetes, obesity & metabolism.

The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors

Shao‐Wei Chen, Yi-Wei Kao, P. Chu, 2020, Cardiovascular Diabetology.

Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan

P. Chang, P. Chu, Chun-Li Wang, 2019, Journal of cardiovascular pharmacology and therapeutics.

The comparison of non-vitamin K antagonist oral anticoagulants versus well-managed warfarin with a lower INR target of 1.5 to 2.5 in Asians patients with non-valvular atrial fibrillation

Yi-Wei Kao, P. Chu, Y. Chan, 2019, PloS one.

Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real‐world study in Taiwan

P. Chang, M. Wen, C. Chou, 2020, ESC heart failure.

The Association of Background Medications on Initial eGFR Change and Kidney Outcomes in Diabetic Patients Receiving SGLT2 Inhibitor

T. Chao, Shao‐Wei Chen, Yi-Wei Kao, 2023, Clinical journal of the American Society of Nephrology : CJASN.